cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Y Mabs Therapeutics Inc
3 own
8 watching
Current Price
$4.5
$-0.06
(-1.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
196.51M
52-Week High
52-Week High
20.48
52-Week Low
52-Week Low
2.94
Average Volume
Average Volume
0.28M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization196.51M
icon52-Week High20.48
icon52-Week Low2.94
iconAverage Volume0.28M
iconDividend Yield--
iconP/E Ratio--
What does the Y Mabs Therapeutics Inc do?
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Read More
How much money does Y Mabs Therapeutics Inc make?
News & Events about Y Mabs Therapeutics Inc.
Globe Newswire
1day ago
Did you lose money on investments in Y-mAbs Therapeutics? If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contactJoseph R. Seidman, Jr. at (877) 779-1414orseidman@bernlieb.com to discuss your rights. NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP...
PR Newswire
1day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB PR Newswire NEW YORK, Feb. 6, 2023 NEW YORK, Feb. 6, 2023...
Globe Newswire
1day ago
BENSALEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ...
Globe Newswire
1day ago
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and Invivyd, ...
Globe Newswire
2days ago
LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingMarch 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (Y-mAbs or the ...
Frequently Asked Questions
Frequently Asked Questions
What is Y Mabs Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Y Mabs Therapeutics Inc shares?
plus_minus_icon
How can I buy Y Mabs Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Y Mabs Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Y Mabs Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Y Mabs Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Y Mabs Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Y Mabs Therapeutics Inc?
plus_minus_icon
What percentage is Y Mabs Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Y Mabs Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.5
$-0.06
(-1.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$5.72
$0.40 (7.52 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$4.49
$-0.04 (-0.88 %)
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$4.85
$0.32 (7.06 %)
Gracell Biotechnologies Inc
Gracell Biotechnologies Inc
$2.50
$0.15 (6.38 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$5.72
$0.40 (7.52 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$4.49
$-0.04 (-0.88 %)
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$4.85
$0.32 (7.06 %)
Gracell Biotechnologies Inc
Gracell Biotechnologies Inc
$2.50
$0.15 (6.38 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00